| Year |
Citation |
Score |
| 2021 |
Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet. Oncology. PMID 34339623 DOI: 10.1016/S1470-2045(21)00336-3 |
0.314 |
|
| 2020 |
Yardley DA, Peacock N, Daniel B, Anz B, Molthrop DC, Shroff SK, Young R, Jankov A, Vander Woude A, Shastry M, Pasek J, DeBusk LM, Hainsworth JD. Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy. Breast Cancer Research and Treatment. PMID 32060783 DOI: 10.1007/s10549-020-05563-z |
0.331 |
|
| 2019 |
Spigel DR, Shipley DL, Waterhouse DM, Jones SF, Ward PJ, Shih KC, Hemphill B, McCleod M, Whorf RC, Page RD, Stilwill J, Mekhail T, Jacobs C, Burris HA, Hainsworth JD. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. The Oncologist. PMID 31420467 DOI: 10.1634/theoncologist.2018-0518 |
0.331 |
|
| 2019 |
Hainsworth JD, Becker KP, Mekhail T, Chowdhary SA, Eakle JF, Wright D, Langdon RM, Yost KJ, Padula GDA, West-Osterfield K, Scarberry M, Shaifer CA, Shastry M, Burris HA, Shih K. Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II). Journal of Neuro-Oncology. PMID 31392595 DOI: 10.1007/S11060-019-03227-7 |
0.304 |
|
| 2019 |
Hainsworth JD. Prolonging remission with rituximab maintenance therapy. Seminars in Oncology. 17-21. PMID 28140104 DOI: 10.1053/j.seminoncol.2003.12.005 |
0.37 |
|
| 2019 |
Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial. Seminars in Oncology. 29: 25-29. PMID 28140088 DOI: 10.1053/sonc.2002.30154 |
0.334 |
|
| 2019 |
Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Seminars in Oncology. 22-27. PMID 28140078 |
0.398 |
|
| 2018 |
Spigel DR, Burris HA, Greco FA, Shih KC, Gian VG, Lipman AJ, Daniel DB, Waterhouse DM, Finney L, Heymach JV, Hainsworth JD. Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures. Cancer. PMID 29645086 DOI: 10.1002/cncr.31290 |
0.346 |
|
| 2018 |
Hainsworth JD, Waterhouse DM, Shih KC, Boccia RV, Priego VM, McCleod MJ, Kudrik FJ, Mitchell RB, Burris HA, Greco FA, Spigel DR. Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 118: 6-12. PMID 29572004 DOI: 10.1016/j.lungcan.2018.01.009 |
0.372 |
|
| 2018 |
Spigel DR, Hainsworth JD, Shipley DL, Mekhail TM, Zubkus JD, Waterhouse DM, Daniel DB, Burris HA, Greco FA. Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium. Lung Cancer (Amsterdam, Netherlands). 117: 38-43. PMID 29496254 DOI: 10.1016/j.lungcan.2018.01.007 |
0.367 |
|
| 2018 |
Spigel DR, Hainsworth JD, Joseph MJ, Shipley DL, Hagan MK, Thompson DS, Burris HA, Greco FA. Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. Cancer. PMID 29451696 DOI: 10.1002/cncr.30986 |
0.372 |
|
| 2017 |
Spigel DR, Rubin MS, Gian VG, Shipley DL, Burris HA, Kosloff RA, Shih KC, Quinn R, Greco FA, Hainsworth JD. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer (Amsterdam, Netherlands). 113: 79-84. PMID 29110854 DOI: 10.1016/j.lungcan.2017.09.007 |
0.355 |
|
| 2017 |
Hurwitz H, Raghav KPS, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Vanderwalde AM, Spigel DR, Bose R, Fakih M, Swanton C, Guo S, Bernaards C, Beattie MS, Sommer N, ... Hainsworth JD, et al. Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Journal of Clinical Oncology. 35: 676-676. DOI: 10.1200/Jco.2017.35.4_Suppl.676 |
0.363 |
|
| 2017 |
Javle MM, Hainsworth JD, Swanton C, Burris HA, Kurzrock R, Sweeney C, Meric-Bernstam F, Spigel DR, Bose R, Guo S, Bernaards C, Beattie MS, Scappaticci FA, Hurwitz H. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. Journal of Clinical Oncology. 35: 402-402. DOI: 10.1200/Jco.2017.35.4_Suppl.402 |
0.337 |
|
| 2017 |
Kurzrock R, Meric-Bernstam F, Hurwitz H, Hainsworth JD, Spigel DR, Bose R, Swanton C, Burris HA, Sweeney C, Yoo B, Beattie MS, Patel R, Schulze K, Lam ET. Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway. Journal of Clinical Oncology. 35: 6086-6086. DOI: 10.1200/Jco.2017.35.15_Suppl.6086 |
0.371 |
|
| 2016 |
Flinn IW, Ruppert AS, Harwin W, Waterhouse D, Papish S, Jones JA, Hainsworth J, Byrd JC. A Phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia (CLL). American Journal of Hematology. PMID 27387131 DOI: 10.1002/ajh.24468 |
0.361 |
|
| 2016 |
Yardley DA, Ward PJ, Daniel BR, Eakle JF, Lamar RE, Lane CM, Hainsworth JD. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. Clinical Breast Cancer. PMID 27340049 DOI: 10.1016/j.clbc.2016.05.006 |
0.317 |
|
| 2016 |
Shih KC, Chowdhary S, Rosenblatt P, Weir AB, Shepard GC, Williams JT, Shastry M, Burris HA, Hainsworth JD. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. Journal of Neuro-Oncology. PMID 27311730 DOI: 10.1007/s11060-016-2172-3 |
0.375 |
|
| 2016 |
Yardley DA, Dickson N, Drosick D, Earwood C, Inhorn R, Murphy P, Hainsworth JD. Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial. Clinical Breast Cancer. PMID 26943991 DOI: 10.1016/j.clbc.2016.02.003 |
0.327 |
|
| 2016 |
Shipley D, Waterhouse DM, Jones SF, Stults DM, Ward PJ, Shih KC, Hemphill MB, McCleod M, Whorf RC, Page RD, Stilwell J, Mekhail T, Anderson K, Jacobs C, Hainsworth JD, et al. The Spruce clinical trial: Double-blind randomized phase II trial of carboplatin and pemetrexed +/- apatorsen in patients with previously untreated stage IV non-squamous non-small-cell lung cancer. Journal of Clinical Oncology. 34: 9092-9092. DOI: 10.1200/JCO.2016.34.15_SUPPL.9092 |
0.316 |
|
| 2015 |
Yardley DA, Peacock NW, Shastry M, Burris HA, Bechhold RG, Hendricks CB, Yoshizawa CN, Sing AP, Hainsworth JD. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Research and Treatment. 154: 299-308. PMID 26507191 DOI: 10.1007/s10549-015-3613-y |
0.337 |
|
| 2015 |
Yardley DA, Bosserman LD, O'Shaughnessy JA, Harwin WN, Morgan SK, Priego VM, Peacock NW, Bass JD, Burris Iii HA, Hainsworth JD. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute. Breast Cancer Research and Treatment. 154: 89-97. PMID 26456573 DOI: 10.1007/s10549-015-3599-5 |
0.379 |
|
| 2015 |
Yardley DA, Shipley DL, Peacock NW, Shastry M, Midha R, Priego VM, Hainsworth JD. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Research and Treatment. 152: 557-67. PMID 26155975 DOI: 10.1007/s10549-015-3482-4 |
0.388 |
|
| 2015 |
Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica. 100: 670-6. PMID 25710456 DOI: 10.3324/haematol.2014.119735 |
0.366 |
|
| 2015 |
Hainsworth JD, Firdaus ID, Earwood CB, Chua CC. Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute. Cancer Investigation. 33: 47-52. PMID 25615852 DOI: 10.3109/07357907.2014.998833 |
0.311 |
|
| 2015 |
Hainsworth JD, Thompson DS, Bismayer JA, Gian VG, Merritt WM, Whorf RC, Finney LH, Dudley BS. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. Cancer Medicine. 4: 673-81. PMID 25556916 DOI: 10.1002/cam4.376 |
0.413 |
|
| 2015 |
Shih KC, Chowdhary SA, Becker KP, Baehring JM, Liggett WH, Burris HA, Hainsworth JD. A phase II study of the combination of BKM120 (buparlisib) and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM). Journal of Clinical Oncology. 33: 2065-2065. DOI: 10.1200/Jco.2015.33.15_Suppl.2065 |
0.368 |
|
| 2014 |
Yardley DA, Raefsky E, Hainsworth JD, Burris HA, Priego V, Inclan A. Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial. Breast Cancer Research and Treatment. 148: 535-40. PMID 25374098 DOI: 10.1007/s10549-014-3189-y |
0.351 |
|
| 2014 |
Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1411-7. PMID 25122437 DOI: 10.1097/JTO.0000000000000274 |
0.309 |
|
| 2014 |
Waterhouse DM, Hainsworth JD, Shih KC, Boccia RV, Priego VM, McCleod M, Townsend DC, Kudrik FJ, Mitchell RB, Burris HA, Greco FA, Spigel DR. Phase II trial of preoperative carboplatin (carbo)/pemetrexed (pem) in patients (pts) with select stage IB-IIIA nonsquamous non-small cell lung cancer (NS-NSCLC). Journal of Clinical Oncology. 32: e18510-e18510. DOI: 10.1200/JCO.2014.32.15_SUPPL.E18510 |
0.32 |
|
| 2014 |
Spigel D, Waterhouse D, Shih K, Boccia R, Priego V, McCleod M, Townsend D, Kudrik F, Mitchell R, Burris H, Hainsworth J, Greco F. Phase 2 Trial of Preoperative Pemetrexed (P)/Carboplatin (C) in Patients (Pts) With Select Stage IB, II, and III Nonsquamous Non-Small Cell Lung Cancer (NS-NSCLC) International Journal of Radiation Oncology*Biology*Physics. 90: S15-S16. DOI: 10.1016/J.IJROBP.2014.08.162 |
0.307 |
|
| 2013 |
Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3926-34. PMID 24101054 DOI: 10.1200/JCO.2012.47.3983 |
0.348 |
|
| 2013 |
Hauke RJ, Infante JR, Rubin MS, Shih KC, Arrowsmith ER, Hainsworth JD. Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium. Melanoma Research. 23: 468-73. PMID 23969699 DOI: 10.1097/CMR.0000000000000014 |
0.396 |
|
| 2013 |
Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spigel DR, Lane CM, Hainsworth JD, Burris HA. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. Cancer Biology & Therapy. 14: 340-6. PMID 23358470 DOI: 10.4161/cbt.23625 |
0.369 |
|
| 2013 |
Spigel DR, Burris HA, Greco FA, Hainsworth JD. Double-blind randomized phase II trial of carboplatin and pemetrexed with or without OGX-427 in patients with previously untreated stage IV non-squamous non-small-cell lung cancer (NSCLC): The Spruce Clinical Trial. Journal of Clinical Oncology. 31: TPS8120-TPS8120. DOI: 10.1200/JCO.2013.31.15_SUPPL.TPS8120 |
0.358 |
|
| 2013 |
Shih KC, Acs P, Burris HA, Hart LL, Kosloff RA, Lamar RE, Hainsworth JD. Phase I study of the combination of BKM120 and bevacizumab in patients with relapsed/refractory glioblastoma multiforme (GBM) or other refractory solid tumors. Journal of Clinical Oncology. 31: e13045-e13045. DOI: 10.1200/JCO.2013.31.15_SUPPL.E13045 |
0.321 |
|
| 2013 |
O'Day S, Gonzalez R, Kim K, Chmielowski B, Kefford R, Long G, Loquai C, Cowey CL, Hauschild A, Hainsworth JD, Hersey P, Boyle F, Evans TRJ, Hamid O, Meneses N, et al. A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. Journal of Clinical Oncology. 31: 9026-9026. DOI: 10.1200/JCO.2013.31.15_SUPPL.9026 |
0.309 |
|
| 2013 |
Waterhouse DM, Stults DM, Daniel DB, Griner PL, Greco FA, Burris HA, Hainsworth JD, Spigel DR. KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 8091-8091. DOI: 10.1200/JCO.2013.31.15_SUPPL.8091 |
0.334 |
|
| 2012 |
Spigel DR, Anthony Greco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA, Hainsworth JD. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 78: 70-5. PMID 22947511 DOI: 10.1016/j.lungcan.2012.06.008 |
0.345 |
|
| 2012 |
Bendell JC, Meluch A, Peyton J, Rubin M, Waterhouse D, Webb C, Burris HA, Hainsworth JD. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clinical Advances in Hematology & Oncology : H&O. 10: 430-7. PMID 22895283 |
0.331 |
|
| 2012 |
Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, Eakle JF, Quinn R, Burris HA, Hainsworth JD. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 77: 359-64. PMID 22560921 DOI: 10.1016/j.lungcan.2012.03.009 |
0.362 |
|
| 2012 |
Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA, Greco FA. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 196-202. PMID 21900836 DOI: 10.1097/JTO.0b013e3182307efe |
0.361 |
|
| 2012 |
Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, Infante JR, Burris HA, Greco FA, Hainsworth JD. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clinical Colorectal Cancer. 11: 45-52. PMID 21840771 DOI: 10.1016/j.clcc.2011.04.002 |
0.309 |
|
| 2012 |
Hauke RJ, Infante JR, Shih KC, Rubin MS, Arrowsmith E, Whorf RC, Hainsworth JD. Everolimus in combination with paclitaxel and carboplatin in patients with advanced melanoma: A phase II trial of the Sarah Cannon Research Institute (SCRI). Journal of Clinical Oncology. 30: 8556-8556. DOI: 10.1200/JCO.2012.30.15_SUPPL.8556 |
0.373 |
|
| 2012 |
Shipley D, Hainsworth JD, Mekhail T, Zubkus JD, Flora DB, Daniel DB, Waterhouse DM, Gravenor D, Burris HA, Greco FA, Spigel DR. Amrubicin and carboplatin with pegfilgrastim in patients with extensive-stage small-cell lung cancer (ES-SCLC): A phase II study of the Sarah Cannon Research Institute (SCRI). Journal of Clinical Oncology. 30: 7100-7100. DOI: 10.1200/JCO.2012.30.15_SUPPL.7100 |
0.34 |
|
| 2012 |
Waterhouse DM, Hainsworth JD, Greco FA, Barnes EK, Lobo CF, Gian V, Joseph MJ, Peyton JD, Huh SY, Daniel DB, Quinn R, Burris HA, Spigel DR. Adjuvant carboplatin, docetaxel, bevacizumab, and erlotinib versus chemotherapy alone in patients with resected non-small cell lung cancer: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). Journal of Clinical Oncology. 30: 7035-7035. DOI: 10.1200/JCO.2012.30.15_SUPPL.7035 |
0.332 |
|
| 2012 |
Barton JH, Raefsky E, Harwin WN, Inclan AA, Miletello G, Hainsworth JD, Burris HA, Yardley DA. Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI). Journal of Clinical Oncology. 30: 1086-1086. DOI: 10.1200/JCO.2012.30.15_SUPPL.1086 |
0.385 |
|
| 2012 |
Yardley DA, Bosserman LD, Peacock NW, Favret A, Morgan SK, Priego VM, Bass JD, Griner PL, Burris HA, Hainsworth JD, O'Shaughnessy J. Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI). Journal of Clinical Oncology. 30: 1018-1018. DOI: 10.1200/JCO.2012.30.15_SUPPL.1018 |
0.31 |
|
| 2012 |
Flinn IW, Cooper RS, Thompson DS, Waselenko JK, Reeves J, Wise RL, Hainsworth JD, Berdeja JG. Fludarabine, Rituximab, and Lenalidomide in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): A Phase I/II Trial of the Sarah Cannon Research Institute Blood. 120: 715-715. DOI: 10.1182/Blood.V120.21.715.715 |
0.319 |
|
| 2012 |
Hainsworth JD, Thompson DS, Greco FA, Raefsky E, Lunin S, Reeves J, Flinn IW. Rituximab +/− Bevacizumab for Patients with Previously Treated Follicular Non-Hodgkins Lymphoma: A Randomized Phase II Trial of the Sarah Cannon Research Institute. Blood. 120: 2749-2749. DOI: 10.1182/BLOOD.V120.21.2749.2749 |
0.365 |
|
| 2012 |
Flinn IW, Mainwaring M, Peacock N, Shipley D, Arrowsmith E, Savona MR, Hainsworth JD, Berdeja JG. Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial. Blood. 120: 2748-2748. DOI: 10.1182/Blood.V120.21.2748.2748 |
0.379 |
|
| 2011 |
Waterhouse DM, Penley WC, Webb CD, Greco FA, Burris HA, Hainsworth JD. Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase I/II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4629. PMID 28023977 DOI: 10.1200/jco.2011.29.15_suppl.4629 |
0.312 |
|
| 2011 |
Spigel DR, Harper PG, Hainsworth JD, De Marinis F, Kabbinavar FF, Kim ES, Lynch TJ, Rosell R, Shepherd FA, Socinski MA, Vergnenegre A. Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS220. PMID 28023554 DOI: 10.1200/jco.2011.29.15_suppl.tps220 |
0.372 |
|
| 2011 |
Yardley DA, Hainsworth JD, Harwin WN, Goble SA, Daniel BR, Ackerman MA, Shipley D, Drosick DR, Hanson SE, Griner PL, Burris HA. TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1103. PMID 28021585 DOI: 10.1200/jco.2011.29.15_suppl.1103 |
0.304 |
|
| 2011 |
Barton JH, Shih KC, Raefsky E, Haines DW, Strike B, Hainsworth JD, Burris HA, Yardley DA. Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1116. PMID 28021559 DOI: 10.1200/jco.2011.29.15_suppl.1116 |
0.307 |
|
| 2011 |
Arkenau H, Infante JR, Bendell JC, Burris HA, Rubin MS, Waterhouse DM, Jones GT, Spigel DR, Hainsworth JD. Lenalidomide in combination with gemcitabine in patients with untreated metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14640. PMID 28021353 DOI: 10.1200/jco.2011.29.15_suppl.e14640 |
0.357 |
|
| 2011 |
Anthony LB, Peeters M, Hainsworth JD, Baudin E, Hoersch D, Klimovsky J, Grouss K, Jehl V, Pavel ME, Yao JC. Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4078. PMID 28020474 DOI: 10.1200/jco.2011.29.15_suppl.4078 |
0.323 |
|
| 2011 |
Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, Krill-Jackson E, Kroener J, Middleman E, Frontiera M, Paul D, Panella T, Bromund J, Zhao L, Orlando M, ... ... Hainsworth J, et al. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clinical Breast Cancer. 11: 211-20. PMID 21723792 DOI: 10.1016/J.Clbc.2011.03.019 |
0.312 |
|
| 2011 |
Gervais R, Hainsworth JD, Blais N, Besse B, Laskin J, Hamm JT, Lipton A, Albain KS, Masters GA, Natale RB, Selaru P, Kim ST, Chao RC, Page RD. Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 74: 474-80. PMID 21680048 DOI: 10.1016/j.lungcan.2011.05.004 |
0.414 |
|
| 2011 |
Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 377: 1846-54. PMID 21621716 DOI: 10.1016/S0140-6736(11)60545-X |
0.34 |
|
| 2011 |
Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM, Whorf RC, Mitchell RB, Daniel DB, Zangmeister J, Bass JD, Hainsworth JD. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2582-9. PMID 21576636 DOI: 10.1200/JCO.2010.30.7678 |
0.335 |
|
| 2011 |
Spigel D, Jones S, Hainsworth J, Infante J, Greco FA, Thompson D, Doss H, Burris H. A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies. Cancer Investigation. 29: 308-12. PMID 21469980 DOI: 10.3109/07357907.2011.568567 |
0.325 |
|
| 2011 |
Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 109-14. PMID 21107290 DOI: 10.1097/JTO.0b013e3181f94ad4 |
0.364 |
|
| 2011 |
Berdeja JG, Couriel DR, Murphy P, Boccia RV, Priego V, Hainsworth JD, Macias-Pérez IM, Flinn IW. A Phase II Trial of Combined Bendamustine, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients Who Are Not Candidates for High-Dose Chemotherapy: Results of a Planned Interim Safety Analysis Blood. 118: 2943-2943. DOI: 10.1182/Blood.V118.21.2943.2943 |
0.312 |
|
| 2010 |
Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, Ganchev H, Pover G, Morris C, Tzekova V. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1630-6. PMID 20802351 DOI: 10.1097/JTO.0b013e3181e8b3a3 |
0.329 |
|
| 2010 |
Yardley DA, McCleod M, Schreiber F, Murphy P, Patton J, Thompson DS, Shastry M, Rubin M, Melnik M, Burris HA, Hainsworth JD. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Investigation. 28: 925-31. PMID 20690806 DOI: 10.3109/07357907.2010.496755 |
0.355 |
|
| 2010 |
Yardley DA, Daniel D, Stipanov M, Drosick DR, Mainwaring M, Peyton J, Shastry M, Hainsworth JD. A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer. Cancer Investigation. 28: 865-71. PMID 20690802 DOI: 10.3109/07357901003631031 |
0.356 |
|
| 2010 |
Yardley DA, Zubkus J, Daniel B, Inhorn R, Lane CM, Vazquez ER, Naot Y, Burris HA, Hainsworth JD. A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clinical Breast Cancer. 10: 367-72. PMID 20670921 DOI: 10.3816/CBC.2010.n.048 |
0.373 |
|
| 2010 |
Yardley D, Burris H, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D, Hainsworth J. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment. 123: 471-5. PMID 20658263 DOI: 10.1007/s10549-010-1047-0 |
0.349 |
|
| 2010 |
Spigel DR, Hainsworth JD, Lane CM, Clark B, Burris HA, Greco FA. Phase II trial of vinflunine in relapsed small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 874-8. PMID 20521355 |
0.32 |
|
| 2010 |
Spigel DR, Hainsworth JD, Gandhi JG, Gian VG, Peyton JD, West-Osterfield K, Clark BL, Vazquez ER, Jones SF, Burris HA, Greco FA. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 862-6. PMID 20521352 DOI: 10.1097/JTO.0b013e3181d86a4f |
0.351 |
|
| 2010 |
Yardley DA, Peacock NW, Dickson NR, White MB, Vázquez ER, Foust JT, Grapski R, Hendricks LK, Scott WL, Hainsworth JD. A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer. Clinical Breast Cancer. 10: 217-23. PMID 20497920 DOI: 10.3816/CBC.2010.n.029 |
0.355 |
|
| 2010 |
Spigel DR, Hainsworth JD, Barton JH, Patton JF, Zubkus JD, Simons L, Griner P, Burris HA, Greco FA. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 841-5. PMID 20421819 DOI: 10.1097/JTO.0b013e3181d737e3 |
0.332 |
|
| 2010 |
Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2213-9. PMID 20351330 DOI: 10.1200/JCO.2009.24.8773 |
0.335 |
|
| 2010 |
Hainsworth JD, Flinn IW, Spigel DR, Clark BL, Griner PL, Vazquez ER, Doss HH, Shipley D, Franco LA, Burris HA, Greco FA. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma, Myeloma & Leukemia. 10: 44-50. PMID 20223728 DOI: 10.3816/CLML.2010.n.004 |
0.311 |
|
| 2010 |
Burris HA, Jones SF, Shipley D, Meluch AA, Greco FA, Barton JH, Yardley DA, Hainsworth JD. Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer. Cancer Investigation. 28: 408-12. PMID 20210519 DOI: 10.3109/07357901003631049 |
0.335 |
|
| 2010 |
Hainsworth JD, Spigel DR, Burris HA, Shipley D, Farley C, Macias-Perez IM, Barton J, Greco FA. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 116: 2448-54. PMID 20209610 DOI: 10.1002/cncr.25029 |
0.312 |
|
| 2010 |
Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer Journal (Sudbury, Mass.). 16: 70-5. PMID 20164695 DOI: 10.1097/PPO.0b013e3181c6aa89 |
0.33 |
|
| 2010 |
Hainsworth JD, Meluch AA, Lane CM, Spigel DR, Burris HA, Gandhi JG, Crane EJ, Stipanov MA, Greco FA. Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium. Cancer Investigation. 28: 275-9. PMID 20158340 DOI: 10.3109/07357900902918460 |
0.3 |
|
| 2010 |
Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA, Greco FA. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 43-8. PMID 19901100 DOI: 10.1200/JCO.2009.24.7353 |
0.335 |
|
| 2010 |
Spigel DR, Lilenbaum R, Hainsworth JD. Trial of poor performance status patients (ToPPS): A randomized phase II trial of pemetrexed versus pemetrexed/bevacizumab versus pemetrexed/carboplatin/bevacizumab in patients with stage IIIb/IV non-small cell lung cancer and ECOG performance status 2. Journal of Clinical Oncology. 28: TPS287-TPS287. DOI: 10.1200/jco.2010.28.15_suppl.tps287 |
0.346 |
|
| 2010 |
Hainsworth JD, Numnum TM, Rao GG. A randomized phase II study of paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer. Journal of Clinical Oncology. 28: TPS257-TPS257. DOI: 10.1200/JCO.2010.28.15_SUPPL.TPS257 |
0.312 |
|
| 2010 |
Daugaard G, Fizazi K, Huebner G, Braumann D, Rubinsak JR, Allouache D, Rodriguez GI, Stahl M, Fuglsang L, Hainsworth JD. An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated carcinoma of unknown primary. Journal of Clinical Oncology. 28: TPS185-TPS185. DOI: 10.1200/JCO.2010.28.15_SUPPL.TPS185 |
0.309 |
|
| 2010 |
Faoro L, Hainsworth JD, Karlin DA, Huang JE, Fang L, Scappaticci FA. BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7583-7583. DOI: 10.1200/JCO.2010.28.15_SUPPL.7583 |
0.361 |
|
| 2010 |
Meluch AA, Bendell JC, Peyton JD, Rudolph P, Rubin MS, Webb CD, Greco FA, Infante JR, Burris HA, Hainsworth JD. A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer. Journal of Clinical Oncology. 28: 4108-4108. DOI: 10.1200/JCO.2010.28.15_SUPPL.4108 |
0.312 |
|
| 2009 |
Hainsworth JD, Lane C, Spigel DR, Shipley D, Waterhouse D, Bury M, Greco FA. Randomized phase III comparison of paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan, both followed by gefitinib, in patients (pts) with carcinoma of unknown primary site (CUP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4631. PMID 27964228 DOI: 10.1200/jco.2009.27.15_suppl.4631 |
0.336 |
|
| 2009 |
Meluch AA, Spigel D, Burris HA, Lane C, Peyton JD, Shipley D, Rubin M, Stipanov M, Greco FA, Hainsworth JD. Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6012. PMID 27962419 DOI: 10.1200/jco.2009.27.15_suppl.6012 |
0.323 |
|
| 2009 |
Peyton JD, Spigel DR, Burris HA, Lane C, Rubin M, Browning M, Trent D, Hainsworth JD. Phase II trial of bevacizumab and everolimus in the treatment of patients with metastatic melanoma: Preliminary results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 9027. PMID 27962097 DOI: 10.1200/jco.2009.27.15_suppl.9027 |
0.327 |
|
| 2009 |
Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, Naot Y, Greco FA. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. The Oncologist. 14: 1189-97. PMID 19965914 DOI: 10.1634/theoncologist.2009-0112 |
0.326 |
|
| 2009 |
Yardley DA, Burris HA, Markus T, Spigel DR, Greco FA, Mainwaring M, Waterhouse DM, Webb CD, Hainsworth JD. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clinical Breast Cancer. 9: 237-42. PMID 19933079 DOI: 10.3816/CBC.2009.n.040 |
0.309 |
|
| 2009 |
Spigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, Yardley DA, Burris HA, Hainsworth JD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1555-60. PMID 19875975 DOI: 10.1097/JTO.0b013e3181bbc540 |
0.36 |
|
| 2009 |
Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, Dannaher C, Greco FA. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clinical Lymphoma & Myeloma. 9: 223-8. PMID 19525191 DOI: 10.3816/CLM.2009.n.044 |
0.357 |
|
| 2009 |
Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR, Fletcher B, Dyehouse K, Ghalie R, Jazieh AR. A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer American Journal of Clinical Oncology: Cancer Clinical Trials. 32: 269-273. PMID 19433964 DOI: 10.1097/Coc.0B013E318187Dd40 |
0.324 |
|
| 2009 |
Infante JR, Yardley DA, Burris HA, Greco FA, Farley CP, Webb C, Spigel DR, Hainsworth JD. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clinical Breast Cancer. 9: 23-8. PMID 19299236 DOI: 10.3816/CBC.2009.n.004 |
0.327 |
|
| 2008 |
Thompson DS, Spigel DR, Hainsworth JD, Jones SF, Burris HA, Sade L, Raefsky E, Greco FA, Yun S, Noursalehi M. Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: Final results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 19023. PMID 27947803 DOI: 10.1200/jco.2008.26.15_suppl.19023 |
0.33 |
|
| 2008 |
Meluch AA, Spigel DR, Burris HA, Greco FA, Gandhi J, Crane E, Markus TM, Hainsworth JD. Vinflunine (VFL) as salvage chemotherapy in hormone-refractory prostate cancer (HRPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 16059. PMID 27947468 DOI: 10.1200/jco.2008.26.15_suppl.16059 |
0.351 |
|
| 2008 |
Spigel DR, Hainsworth JD, Farley C, Meng C, Blake D, Burris HA, Raefsky E, Patton J, Hart LL, Greco FA. Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7554. PMID 27947365 DOI: 10.1200/jco.2008.26.15_suppl.7554 |
0.321 |
|
| 2008 |
Yardley DA, Burris HA, Simons L, Spigel DR, Greco FA, Barton JH, Shipley D, Drosick D, Hainsworth JD. A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clinical Breast Cancer. 8: 425-31. PMID 18952556 DOI: 10.3816/CBC.2008.n.051 |
0.336 |
|
| 2008 |
Hainsworth JD, Spigel DR, Barton J, Farley C, Schreeder M, Hon J, Greco FA. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 113: 765-71. PMID 18543319 DOI: 10.1002/cncr.23606 |
0.34 |
|
| 2008 |
Spigel DR, Lin M, O'Neill V, Hainsworth JD. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. Cancer. 112: 2749-55. PMID 18438878 DOI: 10.1002/cncr.23490 |
0.381 |
|
| 2008 |
Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer. 112: 1288-95. PMID 18189296 DOI: 10.1002/cncr.23271 |
0.318 |
|
| 2008 |
Tzekova V, Cebotaru C, Ciuleanu TE, Damjanov D, Ganchev H, Kanarev V, Stella PJ, Sanders N, Pover G, Hainsworth JD. Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 26: 8029-8029. DOI: 10.1200/JCO.2008.26.15_SUPPL.8029 |
0.303 |
|
| 2008 |
Shipley D, Spigel DR, Hainsworth JD, Whorf RC, Markus TM, Kuzur M, Infante JR, Yardley DA, Burris HA, Greco FA. Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC) Journal of Clinical Oncology. 26: 19073-19073. DOI: 10.1200/JCO.2008.26.15_SUPPL.19073 |
0.341 |
|
| 2008 |
Peacock NW, Infante JR, Yardley DA, Burris HA, Greco FA, Farley C, Webb C, Spigel DR, Hainsworth JD. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC) Journal of Clinical Oncology. 26: 1032-1032. DOI: 10.1200/JCO.2008.26.15_SUPPL.1032 |
0.318 |
|
| 2007 |
Greco FA, Spigel DR, Kuzur ME, Shipley D, Gray JR, Thompson DS, Burris HA, Yardley DA, Pati A, Webb CD, Gandhi JG, Hainsworth JD. Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. Clinical Lung Cancer. 8: 483-7. PMID 17922972 DOI: 10.3816/CLC.2007.n.032 |
0.334 |
|
| 2007 |
Hainsworth JD, Spigel DR, Farley C, Shipley DL, Bearden JD, Gandhi J, Ann Houston G, Anthony Greco F. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer. 110: 2027-34. PMID 17823908 DOI: 10.1002/cncr.23019 |
0.357 |
|
| 2007 |
Spigel DR, Hainsworth JD, Simons L, Meng C, Burris HA, Yardley DA, Grapski R, Schreeder M, Mallidi PV, Greco FA. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 854-61. PMID 17805064 DOI: 10.1097/JTO.0b013e31814617b7 |
0.308 |
|
| 2007 |
Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1747-52. PMID 17470864 DOI: 10.1200/JCO.2006.09.3047 |
0.305 |
|
| 2007 |
Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology. 60: 81-9. PMID 17031646 DOI: 10.1007/s00280-006-0352-0 |
0.353 |
|
| 2007 |
Wyman K, Spigel D, Puzanov I, Hainsworth J, Kelley M, Krozely P, Sturgeon D, Sosman J. A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma Journal of Clinical Oncology. 25: 8539-8539. DOI: 10.1200/jco.2007.25.18_suppl.8539 |
0.352 |
|
| 2007 |
Greco FA, Spigel DR, Burris HA, Shipley DL, Farley C, Gandhi J, Houston GA, Hainsworth JD. Weekly docetaxel versus docetaxel/gemcitabine in elderly/poor performance status (PS) patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC): Randomized phase III trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 25: 7534-7534. DOI: 10.1200/JCO.2007.25.18_SUPPL.7534 |
0.362 |
|
| 2007 |
Knox JJ, Figlin RA, Stadler WM, McDermott DF, Gabrail N, Miller WH, Hainsworth J, Ryan CW, Cupit L, Bukowski RM. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy Journal of Clinical Oncology. 25: 5011-5011. DOI: 10.1200/Jco.2007.25.18_Suppl.5011 |
0.302 |
|
| 2007 |
Meluch AA, Spigel DR, Greco FA, Yardley DA, Burris HA, Farley C, Peyton JD, Shipley DL, Steis RG, Hainsworth JD. Phase I/II trial of preoperative oxaliplatin, docetaxel, capecitabine, and radiation for localized esophageal cancer Journal of Clinical Oncology. 25: 4595-4595. DOI: 10.1200/JCO.2007.25.18_SUPPL.4595 |
0.303 |
|
| 2007 |
Hainsworth JD, Talantov D, Jatkoe T, Meng C, Baden J, Spigel DR, Mazumder A, Wang Y, Greco FA. Gene profiling of tumor tissue in the diagnosis of patients with carcinoma of unknown primary site (CUP): Evaluation of the Veridex 10-gene molecular assay Journal of Clinical Oncology. 25: 21109-21109. DOI: 10.1200/JCO.2007.25.18_SUPPL.21109 |
0.325 |
|
| 2007 |
Spigel DR, Hainsworth JD, Yardley DA, Burris HA, Farley C, Zubkus J, Meng C, Murphy P, Saez R, Greco FA. Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer Journal of Clinical Oncology. 25: 18130-18130. DOI: 10.1200/JCO.2007.25.18_SUPPL.18130 |
0.326 |
|
| 2007 |
Thompson DS, Spigel DR, Greco FA, Yardley DA, Burris HA, Vazquez E, Erland J, Shipley DL, Spremulli E, Hainsworth JD. Preoperative docetaxel and gemcitabine in resectable non-small cell lung cancer: A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 25: 18100-18100. DOI: 10.1200/jco.2007.25.18_suppl.18100 |
0.325 |
|
| 2007 |
Peyton JD, Spigel DR, Hainsworth JD, Yardley DA, Burris HA, Vazquez E, Farley C, Porter L, Lunin S, Greco FA. Phase II trial of vinflunine in patients with relapsed small cell lung cancer Journal of Clinical Oncology. 25: 18091-18091. DOI: 10.1200/jco.2007.25.18_suppl.18091 |
0.342 |
|
| 2007 |
Shipley D, Spigel DR, Cavanaugh C, Moore Y, Hainsworth JD, Jones S, Burris HA, Sade L, Yardley DA, Greco F. Phase II trial of satraplatin and paclitaxel in the first-line treatment of advanced non-small cell lung cancer Journal of Clinical Oncology. 25: 18073-18073. DOI: 10.1200/jco.2007.25.18_suppl.18073 |
0.344 |
|
| 2007 |
Gervais R, Hainsworth J, Blais N, Soria J, Laskin J, Hamm J, Lipton A, Tye L, Chao R, Page R. 6548 POSTER Phase II study of sunitinib malate (SU) as consolidation therapy in patients (pts) with locally-advanced or metastatic non-small cell lung cancer (NSCLC) European Journal of Cancer Supplements. 5: 372. DOI: 10.1016/S1359-6349(07)71376-9 |
0.333 |
|
| 2006 |
Doss HH, Greco FA, Meluch AA, Gray JR, Spigel DR, Shipley DL, Barton JH, Kuzur ME, Ramsey S, Lunin SD, Hainsworth JD. Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 5543. PMID 27954506 DOI: 10.1200/jco.2006.24.18_suppl.5543 |
0.356 |
|
| 2006 |
Hainsworth JD, Yardley DA, Spigel DR, Meluch AA, Rinaldi D, Schnell FM, Greco FA. Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. Cancer Investigation. 24: 469-73. PMID 16939953 DOI: 10.1080/07357900600814060 |
0.335 |
|
| 2006 |
Greco FA, Spigel DR, Barton JH, Farley C, Schreeder MT, Hermann RC, Hainsworth JD. Weekly bortezomib in the treatment of patients (pts) with previously treated multiple myeloma: A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 24: 7547-7547. DOI: 10.1200/JCO.2006.24.18_SUPPL.7547 |
0.319 |
|
| 2006 |
Shipley DL, Hainsworth JD, Spigel DR, Gray JR, Barton JH, Switzer A, Nicolau M, Marsland T, Joseph G, Greco FA. Topotecan: Weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)—A Minnie Pearl Cancer Research Network phase II trial Journal of Clinical Oncology. 24: 7083-7083. DOI: 10.1200/JCO.2006.24.18_SUPPL.7083 |
0.335 |
|
| 2006 |
Thompson DS, Greco FA, Spigel DR, Sosman JA, Burkett E, O’Rourke TJ, Hart L, Hainsworth JD. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: Update of a multicenter phase II trial Journal of Clinical Oncology. 24: 4594-4594. DOI: 10.1200/jco.2006.24.18_suppl.4594 |
0.37 |
|
| 2006 |
Barnes EK, Spigel DR, Greco FA, Meluch AA, Yardley DA, Burris HA, Shipley DL, Patton JF, Farley C, Hainsworth JD. Preoperative oxaliplatin (O), docetaxel (D), capecitabine (C), and concurrent radiation therapy (RT) for patients (pts) with localized esophageal cancer: A phase I/II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 24: 4058-4058. DOI: 10.1200/JCO.2006.24.18_SUPPL.4058 |
0.302 |
|
| 2006 |
Meluch AA, Greco FA, Spigel DR, Gray JR, Thomas M, Meng C, Bearden JD, Rosenoff SH, Hermann RC, Hainsworth JD. Long-term follow-up and compilation of two trials utilizing concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) in patients with localized esophageal cancer involved in the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 24: 4028-4028. DOI: 10.1200/jco.2006.24.18_suppl.4028 |
0.337 |
|
| 2006 |
Hedrick E, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Dong W, Suzuki S, Sugrue M, Grothey A. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE) Journal of Clinical Oncology. 24: 3536-3536. DOI: 10.1200/JCO.2006.24.18_SUPPL.3536 |
0.348 |
|
| 2006 |
Sugrue M, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, Dong W, Sarkar S, Grothey A. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy Journal of Clinical Oncology. 24: 3535-3535. DOI: 10.1200/jco.2006.24.18_suppl.3535 |
0.302 |
|
| 2006 |
Hainsworth JD, Spigel DR, Thompson DS, Shipley DL, Zubkus JD, Toomey MA, Burkett E, Greco FA. Bevacizumab plus erlotinib in patients (pts) with carcinoma of unknown primary site: A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 24: 3033-3033. DOI: 10.1200/JCO.2006.24.18_SUPPL.3033 |
0.351 |
|
| 2006 |
Murphy PB, Hainsworth JD, Spigel DR, Gray JR, Liggett WH, Shipley DL, Switzer A, Gandhi JG, Dannaher CL, Greco FA. Topotecan—Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie Pearl Cancer Research Network phase II trial Journal of Clinical Oncology. 24: 17000-17000. DOI: 10.1200/JCO.2006.24.18_SUPPL.17000 |
0.317 |
|
| 2006 |
Zubkus JD, Hainsworth JD, Spigel DR, Patton JF, Shipley DL, Baskette M, Schnell F, Greco FA. Topotecan, paclitaxel, and carboplatin in advanced ovarian cancer: A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 24: 15015-15015. DOI: 10.1200/JCO.2006.24.18_SUPPL.15015 |
0.32 |
|
| 2006 |
Barton JH, Liggett W, Mainwaring M, Hainsworth JD, Simons L, Spigel DR, Burris III HA, Yardley DA. Phase II pilot trial of imatinib mesylate with weekly docetaxel in metastatic breast cancer Journal of Clinical Oncology. 24: 10716-10716. DOI: 10.1200/JCO.2006.24.18_SUPPL.10716 |
0.318 |
|
| 2006 |
Hainsworth JD, Meng C, Spigel DR, Raefsky EL, Barton JH, Greco FA. Long-Term Followup of Patients with Follicular Lymphoma (FL) Treated with Two Years of Maintenance Rituximab: Response to Rituximab Retreatment at Progression. Blood. 108: 4723-4723. DOI: 10.1182/BLOOD.V108.11.4723.4723 |
0.318 |
|
| 2005 |
Peacock NW, Bearden J, Schnell F, White M, Greco FA, Burris HA, Barton JH, Hainsworth JD, Spigel DR, Yardley DA. Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 704. PMID 27945662 DOI: 10.1200/jco.2005.23.16_suppl.704 |
0.308 |
|
| 2005 |
Kuzur ME, Shipley DL, Spigel DR, Gray JR, Thompson DS, Hainsworth JD, Bradof JE, Webb CD, Gandhi JG, Beschorner A, Greco FA. Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naïve patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7056. PMID 27944505 DOI: 10.1200/jco.2005.23.16_suppl.7056 |
0.362 |
|
| 2005 |
Gray JR, Hainsworth JD, Meluch AA, Spigel DR, Rosenoff SH, Bradof JE, Hermann RC, Meng C, Greco FA. Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) with or without subsequent esophageal resection in patients with localized esophageal cancer: A Minnie Pearl Cancer Research Network trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4018. PMID 27944354 DOI: 10.1200/jco.2005.23.16_suppl.4018 |
0.347 |
|
| 2005 |
Meluch AA, Spigel DS, Greco FA, Barton JH, Messina G, Gould B, Rovito MA, Hainsworth JD. Weekly docetaxel and bortezomib in the treatment of patients with advanced hormone refractory prostate cancer (HRPC): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4735. PMID 27943933 DOI: 10.1200/jco.2005.23.16_suppl.4735 |
0.37 |
|
| 2005 |
Liggett WH, Hainsworth JD, Spigel DR, Meluch AA, Raefsky EL, Kennedy S, Thomas M, Grimaldi M, Saez RA, Greco FA. Fludarabine/rituximab (FR) followed by alemtuzumab as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6556. PMID 27943891 DOI: 10.1200/jco.2005.23.16_suppl.6556 |
0.353 |
|
| 2005 |
Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, Spigel DR, Joseph G, Corso SW, Spremulli E, Hainsworth JD. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. The Oncologist. 10: 728-33. PMID 16249353 DOI: 10.1634/theoncologist.10-9-728 |
0.324 |
|
| 2005 |
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib Journal of Clinical Oncology. 23: 7889-7896. PMID 16204015 DOI: 10.1200/JCO.2005.01.8234 |
0.326 |
|
| 2005 |
Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, Thomas M, Jones SF, Dickson NR, Scullin DC, Bradof JE, Rubinsak JR, Brierre JE, Greco AF. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: A minnie pearl cancer research network phase II trial Clinical Lung Cancer. 7: 127-132. PMID 16179100 DOI: 10.3816/CLC.2005.n.028 |
0.383 |
|
| 2005 |
Hainsworth JD, Spigel DR, Raefsky EL, Kuzur ME, Yost K, Kommor M, Litchy S, Greco FA. Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial. Cancer. 104: 1992-7. PMID 16130138 DOI: 10.1002/cncr.21416 |
0.358 |
|
| 2005 |
Jones SF, Kuhn JG, Greco FA, Raefsky EL, Hainsworth JD, Dickson NR, Thompson DS, Willcutt NT, White MB, Burris HA. A phase I/II study fo exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer Clinical Lung Cancer. 6: 361-366. PMID 15943897 DOI: 10.3816/CLC.2005.N.016 |
0.401 |
|
| 2005 |
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer Journal of Clinical Oncology. 23: 3502-3508. PMID 15908660 DOI: 10.1200/JCO.2005.10.017 |
0.372 |
|
| 2005 |
Hainsworth JD, Meluch AA, Litchy S, Schnell FM, Bearden JD, Yost K, Greco FA. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 103: 2298-303. PMID 15856431 DOI: 10.1002/cncr.21078 |
0.317 |
|
| 2005 |
Hainsworth JD, Kalman L, Castine M, Sylvester L, Greco FA. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: A Minnie Pearl Cancer Research Network phase II trial Gynecologic Oncology. 97: 200-205. PMID 15790459 DOI: 10.1016/j.ygyno.2004.12.036 |
0.391 |
|
| 2005 |
Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1088-95. PMID 15657401 DOI: 10.1200/JCO.2005.12.191 |
0.35 |
|
| 2005 |
Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1500-6. PMID 15632411 DOI: 10.1200/JCO.2005.05.004 |
0.338 |
|
| 2005 |
Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, Bodoky G, Borner M, Laurent D, Jacques C. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) Journal of Clinical Oncology. 23: LBA3-LBA3. DOI: 10.1200/JCO.2005.23.16_SUPPL.LBA3 |
0.326 |
|
| 2005 |
Raefsky EL, Spigel DR, Greco FA, Yardley DA, Bradof JE, Woytowitz DV, Schreeder MT, Liggett WH, Zubkus JD, Petrone D, Hainsworth JD. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 23: 7050-7050. DOI: 10.1200/JCO.2005.23.16_SUPPL.7050 |
0.305 |
|
| 2005 |
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer MA, Fleming GF, Hainsworth JD, Garcia AA, Pegram M, Karlan BY. Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status Journal of Clinical Oncology. 23: 5051-5051. DOI: 10.1200/Jco.2005.23.16_Suppl.5051 |
0.319 |
|
| 2005 |
Hainsworth JD, Sosman JA, Spigel DR, Patton JF, Thompson DS, Sutton V, Hart LL, Yost K, Greco FA. Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial Journal of Clinical Oncology. 23: 4542-4542. DOI: 10.1200/JCO.2005.23.16_SUPPL.4542 |
0.308 |
|
| 2005 |
Hainsworth J, Spigel D, O'Neill V, Klencke B. P-492 A multicenter, open-label, phase Ilia trial of erlotinib in patients with advanced non-small cell lung cancer Lung Cancer. 49: S246. DOI: 10.1016/S0169-5002(05)80985-7 |
0.306 |
|
| 2004 |
Mainwaring MG, Meluch AA, Greco FA, Gian VG, Kohler PC, Lahiry AK, Gandhi JG, Morrissey LH, Hainsworth JD. Weekly docetaxel and estramustine monophosphate (EMP) in the treatment of patients with prostate cancer and persistent/recurrent PSA elevation following primary therapy: A phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4759. PMID 28017073 DOI: 10.1200/jco.2004.22.14_suppl.4759 |
0.308 |
|
| 2004 |
Yardley DA, Greco FA, Porter LL, Burris HA, Phelps C, Webb C, Schlabach L, Fichtel LM, Hainsworth JD. First line treatment with weekly docetaxel, vinorelbine, and trastuzumab in HER2 overexpressing metastatic breast cancer (HER2+ MBC): A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 643. PMID 28017054 DOI: 10.1200/jco.2004.22.14_suppl.643 |
0.35 |
|
| 2004 |
Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by (90)Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6519. PMID 28016918 DOI: 10.1200/jco.2004.22.14_suppl.6519 |
0.307 |
|
| 2004 |
Hambleton J, Novotny WF, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3528. PMID 28016525 DOI: 10.1200/jco.2004.22.14_suppl.3528 |
0.371 |
|
| 2004 |
Dickson NR, Hainsworth JD, Spigel DR, Burris HA, Yardley DA, Thomas M, Jones SF, Scullin DC, Bradof JE, Greco FA. Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7086. PMID 28016132 DOI: 10.1200/jco.2004.22.14_suppl.7086 |
0.336 |
|
| 2004 |
Meluch AA, Greco FA, Burris HA, Erland JB, Khan RA, Rodriguez GI, Gandhi JG, Hainsworth JD. Weekly paclitaxel/estramustine phosphate plus carboplatin administered either weekly or every 4 weeks in the treatment of hormone refractory prostate cancer (HRPC): A randomized phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4659. PMID 28015803 DOI: 10.1200/jco.2004.22.14_suppl.4659 |
0.355 |
|
| 2004 |
Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3617. PMID 28014325 DOI: 10.1200/jco.2004.22.14_suppl.3617 |
0.335 |
|
| 2004 |
Spigel DR, Hainsworth JD, Burris HA, Dannaher C, Hon J, Morrissey LH, Greco FA. Long-term follow-up of limited stage small cell lung cancer patients treated with carboplatin-based chemotherapy and radiotherapy by the Minnie Pearl Cancer Research Network (MPCRN). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7222. PMID 28013900 DOI: 10.1200/jco.2004.22.14_suppl.7222 |
0.368 |
|
| 2004 |
Thompson DS, Hainsworth JD, Morrissey LH, Erland JB, Burris HA, Joseph G, Corso SW, Spremulli E, Greco FA. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network randomized prospective phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7205. PMID 28013844 DOI: 10.1200/jco.2004.22.14_suppl.7205 |
0.333 |
|
| 2004 |
Greco FA, Litchy S, Dannaher C, Hermann RC, Pati A, Hon J, Thompson DS, Hainsworth JD. Carcinoma of unknown primary site with unfavorable characteristics: Survival of 396 patients after treatment with five consecutive phase II trials by the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4186. PMID 28013806 DOI: 10.1200/jco.2004.22.14_suppl.4186 |
0.322 |
|
| 2004 |
Peacock NW, Hainsworth JD, Switzer AB, Burris HA, Barrett C, Nicolau MF, Greco FA. Weekly bolus topotecan as secondary therapy in extensive stage small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7278. PMID 28013600 DOI: 10.1200/jco.2004.22.14_suppl.7278 |
0.34 |
|
| 2004 |
Patton JF, Hainsworth JD, Spigel DR, Burris HA, Yardley DA, Morrissey LH, Sylvester L, Dannaher C, Shipley DL, Greco FA. Weekly bolus topotecan as first-line therapy for extensive stage small cell lung cancer in patients who are elderly, poor performance status, or have severe coexistent illness: A Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7275. PMID 28013597 DOI: 10.1200/jco.2004.22.14_suppl.7275 |
0.356 |
|
| 2004 |
Greco FA, Rodriguez GI, Shaffer DW, Hermann R, Litchy S, Yardley DA, Burris HA, Morrissey LH, Erland JB, Hainsworth JD. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. The Oncologist. 9: 644-52. PMID 15561808 DOI: 10.1634/theoncologist.9-6-644 |
0.346 |
|
| 2004 |
Hainsworth JD, Gray JR, Litchy S, Bearden JD, Shaffer DW, Houston GA, Greco FA. A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer. Clinical Lung Cancer. 6: 33-42. PMID 15310415 DOI: 10.3816/CLC.2004.n.019 |
0.357 |
|
| 2004 |
Hainsworth JD, Carrell D, Drengler RL, Scroggin C, Greco FA. Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer. 100: 2437-41. PMID 15160349 DOI: 10.1002/cncr.20281 |
0.382 |
|
| 2004 |
Burris H, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1621-9. PMID 15117984 DOI: 10.1200/JCO.2004.08.065 |
0.336 |
|
| 2004 |
Hainsworth JD. Prolonging Remission with Rituximab Maintenance Therapy Seminars in Oncology. 31: 17-21. PMID 15042530 |
0.368 |
|
| 2004 |
Hainsworth JD, Greco FA. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer. Clinical Lung Cancer. S17-22. PMID 14720343 DOI: 10.3816/clc.2002.s.009 |
0.369 |
|
| 2004 |
Gerena Lewis MA, Shukla R, Kleykamp B, Jazieh AR, Hainsworth J. A phase II trial of denileukin difititox–in previously treated, advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 22: 7292-7292. DOI: 10.1200/JCO.2004.22.90140.7292 |
0.301 |
|
| 2004 |
Shipley DL, Spigel DR, Carrell DL, Dannaher C, Greco FA, Hainsworth JD. Phase II trial of rituximab and short duration chemotherapy followed by 90Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network phase II trial Journal of Clinical Oncology. 22: 6519-6519. DOI: 10.1200/JCO.2004.22.90140.6519 |
0.323 |
|
| 2004 |
Greco FA, Litchy S, Dannaher C, Hermann RC, Pati A, Hon J, Thompson DS, Hainsworth JD. Carcinoma of unknown primary site with unfavorable characteristics: Survival of 396 patients after treatment with five consecutive phase II trials by the Minnie Pearl Cancer Research Network Journal of Clinical Oncology. 22: 4186-4186. DOI: 10.1200/JCO.2004.22.90140.4186 |
0.325 |
|
| 2004 |
Doss HH, Hainsworth JD, Spigel DR, Kommor M, Zakem M, Raefsky EL, Litchy S, Greco FA. Gemcitabine and irinotecan in patients with previously treated carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network phase II trial Journal of Clinical Oncology. 22: 4167-4167. DOI: 10.1200/JCO.2004.22.90140.4167 |
0.31 |
|
| 2004 |
Fyfe GA, Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Kabbinavar F, Holmgren E, Novotny W. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups Journal of Clinical Oncology. 22: 3617-3617. DOI: 10.1200/JCO.2004.22.90140.3617 |
0.322 |
|
| 2004 |
Friedberg J, Cohen P, Kerr RO, Robinson KS, Forero-Torres A, van der Jagt R, Camacho E, Hainsworth J, Roeck B, Multani PS. SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL). Blood. 104: 2480-2480. DOI: 10.1182/BLOOD.V104.11.2480.2480 |
0.354 |
|
| 2003 |
Greco FA, Hainsworth JD. Emerging role of topotecan in first-line therapy of small-cell lung cancer. Clinical Lung Cancer. 4: 279-87. PMID 14609445 DOI: 10.3816/clc.2003.n.007 |
0.369 |
|
| 2003 |
Hainsworth JD, Mainwaring MG, Thomas M, Porter LL, Gian VG, Jones SF, Greco FA. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Clinical Lung Cancer. 4: 347-55. PMID 14599303 DOI: 10.3816/CLC.2003.N.014 |
0.397 |
|
| 2003 |
Hainsworth JD, Erland JB, Barton JH, Thompson DS, Stagg MP, Bradof JE, Twele TW, Greco EA. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clinical Lung Cancer. 5: 33-8. PMID 14596701 DOI: 10.3816/CLC.2003.N.019 |
0.414 |
|
| 2003 |
Hainsworth J, Vergote I, Janssens J. A review of phase II studies of ZD9331 treatment for relapsed or refractory solid tumours Anti-Cancer Drugs. 14. PMID 14567436 |
0.386 |
|
| 2003 |
Meluch AA, Greco FA, Gray JR, Thomas M, Sutton VM, Davis JL, Kalman LA, Shaffer DW, Yost K, Rinaldi DA, Hainsworth JD. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer Journal (Sudbury, Mass.). 9: 251-60. PMID 12967135 DOI: 10.1097/00130404-200307000-00007 |
0.33 |
|
| 2003 |
Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin C, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade Non-Hodgkin's lymphoma: Phase II trial Clinical Lymphoma. 4: 36-42. PMID 12837153 DOI: 10.3816/CLM.2003.N.012 |
0.35 |
|
| 2003 |
Hainsworth JD, Burris HA, Erland JB, Baker M, Scullin DC, Shaffer DW, Greco FA. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Investigation. 21: 193-9. PMID 12743984 DOI: 10.1081/CNV-120016415 |
0.415 |
|
| 2003 |
Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1746-51. PMID 12721250 DOI: 10.1200/JCO.2003.09.027 |
0.314 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
Hainsworth JD. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Seminars in Oncology. 30: 9-15. PMID 12652459 DOI: 10.1053/sonc.2003.50023 |
0.35 |
|
| 2003 |
West W, Birch R, Schnell F, Hainsworth J, Tongol J, Campos L. Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer. The Oncologist. 8: 76-82. PMID 12604734 DOI: 10.1634/THEONCOLOGIST.8-1-76 |
0.332 |
|
| 2003 |
Greco FA, Hainsworth JD. Emerging role of topotecan in first-line therapy of small-cell lung cancer Clinical Lung Cancer. 4: 279-287. |
0.369 |
|
| 2002 |
Gridelli C, Hainsworth J. Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC Lung Cancer. 38. PMID 12480193 DOI: 10.1016/S0169-5002(02)00251-9 |
0.373 |
|
| 2002 |
Hainsworth JD, Calvert S, Greco FA. Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Investigation. 20: 863-71. PMID 12449715 DOI: 10.1081/CNV-120005897 |
0.322 |
|
| 2002 |
Greco FA, Gray JR, Thompson DS, Burris HA, Erland JB, Barton JH, Litchy S, Houston GA, Butts JA, Webb C, Scott C, Hainsworth JD. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial. Cancer. 95: 1279-85. PMID 12216096 DOI: 10.1002/cncr.10810 |
0.357 |
|
| 2002 |
Hainsworth JD, Meluch AA, McClurkan S, Gray JR, Stroup SL, Burris HA, Yardley DA, Bradof JE, Yost K, Ellis JK, Greco FA. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Journal (Sudbury, Mass.). 8: 311-21. PMID 12184409 DOI: 10.1097/00130404-200207000-00007 |
0.326 |
|
| 2002 |
Hainsworth JD, Gray JR, Morrissey LH, Kalman LA, Hon JK, Greco FA. Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2937-42. PMID 12089222 DOI: 10.1200/JCO.2002.10.071 |
0.34 |
|
| 2002 |
Hainsworth JD, Morrissey LH, Scullin DC, Houston GA, Prasthofer EF, Gray JR, Burris HA, Greco FA. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer. 94: 2426-33. PMID 12033195 DOI: 10.1002/cncr.10508 |
0.37 |
|
| 2002 |
Greco FA, Burris HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1651-6. PMID 11896116 DOI: 10.1200/JCO.20.6.1651 |
0.326 |
|
| 2002 |
Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1182-91. PMID 11870159 |
0.335 |
|
| 2002 |
Hainsworth JD. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial Seminars in Oncology. 29: 25-29. PMID 11842385 |
0.334 |
|
| 2002 |
Hainsworth JD, Burris HA, Billings FT, Bradof JE, Baker M, Greco FA. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network. Cancer. 92: 2391-8. PMID 11745295 DOI: 10.1002/1097-0142(20011101)92:9<2391::AID-CNCR1587>3.0.CO;2-M |
0.353 |
|
| 2002 |
Hainsworth JD, Greco FA. The role of weekly docetaxel in the treatment of advanced non-small-cell lung cancer Clinical Lung Cancer. 3. |
0.369 |
|
| 2001 |
Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3500-5. PMID 11481356 DOI: 10.1200/JCO.2001.19.15.3500 |
0.323 |
|
| 2001 |
Hainsworth JD, Burris HA, Greco FA. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: A review of the Sarah Cannon Cancer Center experience Seminars in Oncology. 28: 43-47. PMID 11479897 |
0.405 |
|
| 2001 |
Hainsworth JD, Burris HA, Greco FA. Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer Seminars in Oncology. 28: 21-25. PMID 11441411 |
0.39 |
|
| 2001 |
Meluch AA, Greco FA, Burris HA, O'Rourke T, Ortega G, Steis RG, Morrissey LH, Johnson V, Hainsworth JD. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 3018-24. PMID 11408496 DOI: 10.1200/JCO.2001.19.12.3018 |
0.339 |
|
| 2001 |
Hainsworth JD, Burris HA, Calvert SW, Willcutt NT, Scullin DC, Bramham J, Greco FA. Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer Investigation. 19: 335-9. PMID 11405172 DOI: 10.1081/CNV-100103127 |
0.398 |
|
| 2001 |
Hainsworth JD, Vokes EE. Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer Seminars in Oncology. 28: 22-27. PMID 11284621 |
0.396 |
|
| 2000 |
Hainsworth JD. Rituximab as first-line systemic therapy for patients with low-grade lymphoma Seminars in Oncology. 27: 25-29. PMID 11225997 |
0.316 |
|
| 2000 |
Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies Oncologist. 5: 376-384. PMID 11040273 |
0.306 |
|
| 2000 |
Greco FA, Burris HA, Hainsworth JD. Gemcitabine, paclitaxel, and garboplatin for advanced non-small-cell lung cancer Oncology. 14: 31-34. PMID 10960943 |
0.406 |
|
| 2000 |
Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Barton JH, Bradof JE, Greco FA. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer. 89: 328-33. PMID 10918162 DOI: 10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F |
0.375 |
|
| 2000 |
Meluch AA, Burris HS, Greco FA, Hainsworth JD. Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium European Journal of Cancer. 36. PMID 10908846 |
0.354 |
|
| 2000 |
Hainsworth JD, Greco FA. Management of patients with cancer of unknown primary site Oncology. 14: 563-574. PMID 10826316 |
0.327 |
|
| 2000 |
Greco FA, Erland JB, Morrissey LH, Burris HA, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 11: 211-5. PMID 10761758 DOI: 10.1023/A:1008369812295 |
0.329 |
|
| 2000 |
Hainsworth JD, Burris HA, Litchy S, Erland JB, Hon JK, Brierre JE, Greco FA. Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial. Cancer. 88: 1353-8. PMID 10717616 DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1353::AID-CNCR11>3.0.CO;2-A |
0.36 |
|
| 2000 |
Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC, Bearden JD, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma Blood. 95: 3052-3056. DOI: 10.1182/BLOOD.V95.10.3052.010K30_3052_3056 |
0.335 |
|
| 1999 |
Hainsworth JD. Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues Drugs. 58: 51-56. PMID 10711842 |
0.335 |
|
| 1999 |
Greco FA, Hainsworth JD. Paclitaxel-based therapy in non-small-cell lung cancer: Improved third generation chemotherapy Annals of Oncology. 10. PMID 10582142 |
0.34 |
|
| 1999 |
Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: Review of safety and efficacy Cancer Journal From Scientific American. 5: 179-191. PMID 10367176 |
0.305 |
|
| 1999 |
Greco FA, Hainsworth JD. The evolving role of paclitaxel for patients with carcinoma of unknown primary site Seminars in Oncology. 26: 129-133. PMID 10190795 |
0.324 |
|
| 1999 |
Hainsworth JD, Greco FA. The current role and future prospects of paclitaxel in the treatment of small cell lung cancer Seminars in Oncology. 26: 60-66. PMID 10190785 |
0.386 |
|
| 1999 |
Hainsworth JD, Burris HA, Erland JB, Morrissey LH, Meluch AA, Kalman LA, Hon JK, Scullin DC, Smith SW, Greco FA. Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma. Cancer. 85: 1269-76. PMID 10189131 DOI: 10.1002/(SICI)1097-0142(19990315)85:6<1269::AID-CNCR8>3.0.CO;2-I |
0.343 |
|
| 1999 |
Hainsworth JD, Burris HA, Morrissey LH, Greco FA. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer. Cancer. 85: 1179-85. PMID 10091804 DOI: 10.1002/(SICI)1097-0142(19990301)85:5<1179::AID-CNCR23>3.0.CO;2-I |
0.314 |
|
| 1999 |
Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 85: 786-95. PMID 10091755 DOI: 10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9 |
0.333 |
|
| 1999 |
Greco FA, Hainsworth JD. Introduction to the first comprehensive conference on oral chemotherapy for the treatment of patients with cancer Drugs. 58. |
0.325 |
|
| 1998 |
Schwartzberg LS, Birch R, West WH, Tauer KW, Wittlin F, Leff R, Campos L, Rymer W, Carter P, Mangum M, Greco FA, Hainsworth J, Raefsky E, Blanco R, Buckner CD, et al. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-III breast cancer: outpatient administration in community cancer centers. American Journal of Clinical Oncology. 21: 523-31. PMID 9781614 DOI: 10.1097/00000421-199810000-00022 |
0.33 |
|
| 1998 |
Hainsworth JD, Urba WJ, Hon JK, Thompson KA, Stagg MP, Hopkins LG, Thomas M, Greco FA. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial. European Journal of Cancer (Oxford, England : 1990). 34: 654-8. PMID 9713269 DOI: 10.1016/S0959-8049(97)10103-4 |
0.414 |
|
| 1998 |
Hainsworth JD, Burris HA, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2164-8. PMID 9626217 DOI: 10.1200/JCO.1998.16.6.2164 |
0.33 |
|
| 1998 |
Anthony Greco F, Hainsworth JD. One-hour paclitaxel plus carboplatin for advanced non-small-cell lung cancer Oncology. 12: 71-73. PMID 9516616 |
0.392 |
|
| 1998 |
Hainsworth JD, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin, and extended-schedule oral etoposide for small- cell lung cancer Oncology. 12: 31-35. PMID 9516609 |
0.364 |
|
| 1997 |
Greco FA, Hainsworth JD. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site Seminars in Oncology. 24. PMID 9427278 |
0.367 |
|
| 1997 |
Hainsworth JD, Meluch AA, Greco FA. Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: Preliminary results of phase II trial Seminars in Oncology. 24. PMID 9427264 |
0.376 |
|
| 1997 |
Weaver CH, Greco FA, Hainsworth JD, Zhen B, Baldwin P, Wittlin F, Lewis M, West WH, Schwartzberg L, Buckner CD. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Bone Marrow Transplantation. 20: 847-53. PMID 9404925 DOI: 10.1038/sj.bmt.1700976 |
0.371 |
|
| 1997 |
Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 3464-70. PMID 9396399 DOI: 10.1200/JCO.1997.15.12.3464 |
0.336 |
|
| 1997 |
Weaver CH, Schwartzberg L, Zhen B, Mangum M, Leff R, Tauer K, Rosenberg A, Pendergrass K, Kaywin P, Hainsworth J, Greco FA, West WH, Buckner CD. High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: results of outpatient treatment in community cancer centers. Bone Marrow Transplantation. 20: 753-60. PMID 9384477 DOI: 10.1038/sj.bmt.1700975 |
0.347 |
|
| 1997 |
Gresco FA, Hainsworth JD. Paclitaxel with mitoxantrone with or without 5-fluorouracil and high- dose leucovorin in the treatment of metastatic breast cancer Seminars in Oncology. 24. PMID 9374096 |
0.331 |
|
| 1997 |
Greco FA, Hainsworth JD. Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial Seminars in Oncology. 24. PMID 9331113 |
0.417 |
|
| 1997 |
Weaver CH, Schwartzberg LS, Hainsworth J, Greco FA, Li W, Buckner CD, West WH. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers. Bone Marrow Transplantation. 19: 671-8. PMID 9156243 DOI: 10.1038/sj.bmt.1700713 |
0.332 |
|
| 1997 |
Weaver CH, West WH, Schwartzberg LS, Alberico T, Leff R, Greco FA, Hainsworth J, Birch R, McAneny B, Magee M, Raefsky E, Kalman L, Buckner CD. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplantation. 19: 661-70. PMID 9156242 DOI: 10.1038/sj.bmt.1700728 |
0.33 |
|
| 1997 |
Hainsworth JD. Chemotherapy in the treatment of non-small cell lung cancer American Family Physician. 55: 2265-2272. PMID 9149654 |
0.307 |
|
| 1997 |
Greco FA, Hainsworth JD. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung Oncology. 11: 27-36. PMID 9115851 |
0.327 |
|
| 1997 |
Rubenstein EB, Gralla RJ, Hainsworth JD, Hesketh PJ, Grote TH, Modiano MR, Khojasteh A, Kalman LA, Benedict CR, Hahne WF. Randomized, double blind, dose-response trial across four oral doses of dolasetron for the prevention of acute emesis after moderately emetogenic chemotherapy Cancer. 79: 1216-1224. PMID 9070501 DOI: 10.1002/(SICI)1097-0142(19970315)79:6<1216::AID-CNCR22>3.0.CO;2-1 |
0.33 |
|
| 1997 |
Hainsworth JD, Jolivet J, Birch R, Hopkins LG, Greco FA. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in frist-line chemotherapy for patients with metastatic breast carcinoma: A randomized Phase II trial Cancer. 79: 740-748. PMID 9024712 DOI: 10.1002/(sici)1097-0142(19970215)79:4<740::aid-cncr11>3.0.co;2 |
0.357 |
|
| 1996 |
Hainsworth JD, Greco FA. One-hour paclitaxel in the treatment of non-small cell lung cancer Seminars in Oncology. 23: 98-101. PMID 9007133 |
0.344 |
|
| 1996 |
Greco FA, Hainsworth JD. Paclitaxel via 1-hour infusion: Clinical experience Seminars in Oncology. 23: 91-93. PMID 9007131 |
0.357 |
|
| 1996 |
Greco FA, Hainsworth JD. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer Seminars in Oncology. 23: 7-10. PMID 9007113 |
0.41 |
|
| 1996 |
Greco FA, Hainsworth JD. Paclitaxel via 1-hour infusion: Rationale and pharmacology Seminars in Oncology. 23: 19-20. PMID 8996592 |
0.378 |
|
| 1996 |
Greco FA, Hainsworth JD. Clinical studies with etoposide phosphate Seminars in Oncology. 23: 45-50. PMID 8996575 |
0.343 |
|
| 1996 |
Hainsworth JD, Stroup SL, Greco FA. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma Cancer. 77: 2458-2463. PMID 8640693 DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2458::AID-CNCR7>3.0.CO;2-I |
0.397 |
|
| 1996 |
Greco FA, Stroup SL, Gray JR, Hainsworth JD. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 1642-8. PMID 8622083 |
0.367 |
|
| 1996 |
Hainsworth JD, Jones SE, Mennel RG, Blum JL, Greco FA. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 1611-6. PMID 8622079 DOI: 10.1200/JCO.1996.14.5.1611 |
0.31 |
|
| 1995 |
Hainsworth JD, Greco FA. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy Seminars in Oncology. 22: 45-49. PMID 8643970 |
0.41 |
|
| 1995 |
Hainsworth JD, Levitan N, Wampler GL, Belani CP, Seyedsadr MS, Randolph J, Schacter LP, Greco FA. Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 13: 1436-42. PMID 7751890 DOI: 10.1200/JCO.1995.13.6.1436 |
0.324 |
|
| 1995 |
Greco FA, Stroup SL, Hainsworth JD. Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer Seminars in Oncology. 22: 75-77. PMID 7644932 |
0.387 |
|
| 1995 |
Hainsworth JD, Thompson DS, Greta FA. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small- cell lung cancer Journal of Clinical Oncology. 13: 1609-1614. PMID 7602349 |
0.355 |
|
| 1995 |
Greco FA, Hainsworth JD. One-hour paclitaxel infusion schedules: A phase I/II comparative trial Seminars in Oncology. 22: 118-123. PMID 7597427 |
0.339 |
|
| 1995 |
Greco FA, Hainsworth JD. Etoposide phosphate or etoposide with cisplatin in the treatment of small cell lung cancer: Randomized Phase II trial Lung Cancer. 12. PMID 7551961 |
0.405 |
|
| 1994 |
Greco FA, Hainsworth JD. Paclitaxel (Taxol): Phase I/II trial comparing 1-hour infusion schedules Seminars in Oncology. 21: 3-8. PMID 7939760 |
0.346 |
|
| 1994 |
Hainsworth JD, Greco FA. Paclitaxel administered by 1-hour infusion: Preliminary results of a phase I/II trial comparing two schedules Cancer. 74: 1377-1382. PMID 7914470 DOI: 10.1002/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U |
0.34 |
|
| 1994 |
Greco FA, Hainsworth JD. Practical approaches to the treatment of patients with extensive stage small cell lung cancer Seminars in Oncology. 21: 3-6. PMID 7522349 |
0.303 |
|
| 1993 |
Hainsworth JD. Chronic administration of etoposide in the treatment of non-hodgkin's lymphoma Leukemia and Lymphoma. 10: 65-72. PMID 8481673 DOI: 10.3109/10428199309149115 |
0.364 |
|
| 1993 |
Butler RD, Hainsworth JD. Optimal therapy for small noncleaved cell lymphoma Cancer Treatment and Research. 66: 65-79. PMID 8102864 |
0.314 |
|
| 1993 |
Waits TM, Greco FA, Greer JP, Hainsworth JD. Treatment of poor prognosis non-hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: Long-term followup Leukemia and Lymphoma. 10: 453-459. PMID 7691308 DOI: 10.3109/10428199309148202 |
0.327 |
|
| 1993 |
Hainsworth JD. The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer Annals of Oncology. 4. PMID 7688982 |
0.361 |
|
| 1993 |
Waits TM, Greco FA, Greer JP, Johnson DH, Wolff SN, Stein RS, McMaster ML, Hainsworth JD. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 943-9. PMID 7683712 DOI: 10.1200/JCO.1993.11.5.943 |
0.309 |
|
| 1992 |
Greco FA, Hainsworth JD. Tumors of unknown origin Ca-a Cancer Journal For Clinicians. 42: 96-115. PMID 1540854 |
0.341 |
|
| 1992 |
Greco FA, Johnson DH, Hainsworth JD. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site Seminars in Oncology. 19: 14-18. PMID 1492223 |
0.341 |
|
| 1992 |
Hainsworth JD, Johnson DH, Greco FA. Chronic etoposide schedules in the treatment of non-Hodgkin's lymphoma Seminars in Oncology. 19: 13-18. PMID 1488651 |
0.323 |
|
| 1992 |
Hainsworth JD. The use of ondansetron in patients receiving multiple-day cisplatin regimens Seminars in Oncology. 19: 48-52. PMID 1387250 |
0.304 |
|
| 1992 |
Hainsworth JD, Johnson DH, Greco FA. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site Seminars in Oncology. 19: 54-58. PMID 1384145 |
0.34 |
|
| 1992 |
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience Journal of Clinical Oncology. 10: 912-922. PMID 1375284 |
0.321 |
|
| 1992 |
Johnson DH, Hainsworth JD, DeVore R, Hande KR, Greco FA. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer. Preliminary results of a Vanderbilt trial. Oncology. 57-61; discussion 61. PMID 1323813 DOI: 10.1159/000227112 |
0.329 |
|
| 1992 |
Greco FA, Murphy PB, Hainsworth JD, Hande KR, Johnson DH. Prolonged administration of oral etoposide plus cisplatin in extensive stage small cell lung cancer. Oncology. 34-8; discussion 39. PMID 1323810 DOI: 10.1159/000227108 |
0.302 |
|
| 1992 |
Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA. Prolonged administration of oral etoposide in non-small-cell lung cancer: A phase II trial Journal of Clinical Oncology. 10: 292-296. PMID 1310104 DOI: 10.1200/JCO.1992.10.2.292 |
0.372 |
|
| 1992 |
Murphy PB, Hainsworth JD, Greco FA, Hande KR, DeVore RF, Johnson DH. A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer. 69: 370-5. PMID 1309432 DOI: 10.1002/1097-0142(19920115)69:2<370::AID-CNCR2820690217>3.0.CO;2-E |
0.36 |
|
| 1991 |
Hainsworth JD, Johnson DH, Greco FA. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site Cancer. 67: 310-314. PMID 1984833 |
0.337 |
|
| 1991 |
Greco FA, Johnson DH, Hainsworth JD. Chronic oral etoposide. Cancer. 67: 303-9. PMID 1984832 DOI: 10.1002/1097-0142(19910101)67:1+<303::AID-CNCR2820671316>3.0.CO;2-4 |
0.354 |
|
| 1991 |
Hainsworth JD, Andrews MB, Johnson DH, Greco FA. Mitoxantrone, fluorouracil, and high-dose leucovorin: An effective, well-tolerated regimen for metastatic breast cancer Journal of Clinical Oncology. 9: 1731-1736. PMID 1919624 |
0.335 |
|
| 1991 |
Greco FA, Johnson DH, Hainsworth JD. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer Cancer Treatment Reviews. 18: 47-55. PMID 1904309 DOI: 10.1016/0305-7372(91)90024-T |
0.318 |
|
| 1991 |
Hainsworth JD, Greco FA. Treatment of patients with cancer of unknown primary site Important Advances in Oncology. 173-190. PMID 1869276 |
0.325 |
|
| 1991 |
Johnson DH, Hainsworth JD, Hande KR, Greco FA. Current status of etoposide in the management of small cell lung cancer Cancer. 67: 231-244. PMID 1845846 |
0.331 |
|
| 1991 |
McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 941-6. PMID 1709685 DOI: 10.1200/JCO.1991.9.6.941 |
0.322 |
|
| 1991 |
McMaster ML, Johnson DH, Greer JP, Wolff SN, Hildreth CR, Greco FA, Hainsworth JD. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer. 67: 1487-92. PMID 1705861 DOI: 10.1002/1097-0142(19910315)67:6<1487::AID-CNCR2820670604>3.0.CO;2-S |
0.352 |
|
| 1991 |
Johnson DH, Strupp J, Greco FA, Stewart J, Merrill W, Malcolm A, Hande KR, Hainsworth JD. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer. Cancer. 68: 1216-20. PMID 1651802 DOI: 10.1002/1097-0142(19910915)68:6<1216::AID-CNCR2820680606>3.0.CO;2-G |
0.38 |
|
| 1990 |
Hainsworth JD. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma Journal of Clinical Oncology. 8: 502-508. PMID 2407811 |
0.353 |
|
| 1990 |
Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 8: 1613-7. PMID 2170589 DOI: 10.1200/JCO.1990.8.10.1613 |
0.385 |
|
| 1990 |
Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide in refractory lymphoma. European Journal of Cancer (Oxford, England : 1990). 26: 818-21. PMID 2145902 DOI: 10.1016/0277-5379(90)90160-U |
0.313 |
|
| 1990 |
Hainsworth JD, Jones HW, Burnett LS, Johnson DH, Greco FA. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). American Journal of Clinical Oncology. 13: 410-5. PMID 2121019 DOI: 10.1097/00000421-199010000-00009 |
0.333 |
|
| 1989 |
Hainsworth JD, Johnson DH, Frazier SR, Greco FA. Chronic daily administration of oral etoposide--a phase I trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 396-401. PMID 2918334 DOI: 10.1200/JCO.1989.7.3.396 |
0.337 |
|
| 1989 |
Loehrer PJ, Sledge GW, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, Omura G, Braun TJ. Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 1655-9. PMID 2681554 DOI: 10.1200/JCO.1989.7.11.1655 |
0.34 |
|
| 1989 |
Hainsworth JD, Johnson DH, Hande KR, Greco FA. Chemotherapy of advanced non-small-cell lung cancer: A randomized trial of three cis-platin-based chemotherapy regimens American Journal of Clinical Oncology: Cancer Clinical Trials. 12: 345-349. PMID 2547305 |
0.325 |
|
| 1989 |
Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 607-12. PMID 2540288 DOI: 10.1200/JCO.1989.7.5.607 |
0.32 |
|
| 1988 |
DeLeo MJ, Greco FA, Hainsworth JD, Johnson DH. Late recurrences in long-term survivors of germ cell neoplasms Cancer. 62: 985-988. PMID 3409178 |
0.315 |
|
| 1988 |
Hainsworth JD, Grosh WW, Burnett LS, Jones HW, Wolff SN, Greco FA. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Annals of Internal Medicine. 108: 165-70. PMID 3124679 DOI: 10.7326/0003-4819-108-2-165 |
0.3 |
|
| 1988 |
Hainsworth JD, Johnson DH, Farese RV, Macey JW, Vaughn WK, Greco FA. Limited stage small cell lung cancer: analysis of clinical prognostic factors. Southern Medical Journal. 80: 1518-22. PMID 2827319 DOI: 10.1097/00007611-198712000-00008 |
0.305 |
|
| 1988 |
Hainsworth JD, Dial TW, Greco FA. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site American Journal of Clinical Oncology: Cancer Clinical Trials. 11: 138-145. PMID 2451881 |
0.31 |
|
| 1987 |
Johnson DH, DeLeo MJ, Hande KR, Wolff SN, Hainsworth JD, Greco FA. High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 5: 703-9. PMID 3033161 DOI: 10.1200/JCO.1987.5.5.703 |
0.312 |
|
| 1987 |
Hainsworth JD, Wright EP, Gray GF, Greco FA. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 5: 1275-80. PMID 2442318 DOI: 10.1200/JCO.1987.5.8.1275 |
0.324 |
|
| 1986 |
Giannone L, Greco FA, Hainsworth JD. Combination intraventricular chemotherapy for meningeal neoplasia Journal of Clinical Oncology. 4: 68-73. PMID 3079822 |
0.372 |
|
| 1986 |
Johnson DH, Porter LL, List AF, Hande KR, Hainsworth JD, Greco FA. Acute nonlymphocytic leukemia after treatment of small cell lung cancer. The American Journal of Medicine. 81: 962-8. PMID 3026177 DOI: 10.1016/0002-9343(86)90388-8 |
0.321 |
|
| 1986 |
List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 4: 1191-8. PMID 3016206 DOI: 10.1200/Jco.1986.4.8.1191 |
0.318 |
|
| 1986 |
Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. An indolent disease. The American Journal of Medicine. 81: 381-6. PMID 2428242 DOI: 10.1016/0002-9343(86)90286-X |
0.308 |
|
| 1985 |
Prager RL, Foster JM, Hainsworth JD, Hande KR, Johnson DH, Wolff SN, Greco FA, Bender HW. The feasibility of adjuvant surgery in limited-stage small cell carcinoma: a prospective evaluation. The Annals of Thoracic Surgery. 38: 622-6. PMID 6095776 DOI: 10.1016/S0003-4975(10)62322-3 |
0.301 |
|
| 1985 |
Greco FA, Johnson DH, Hainsworth JD, Wolff SN. Chemotherapy of small-cell lung cancer Seminars in Oncology. 12: 31-37. PMID 3001942 |
0.347 |
|
| 1985 |
Johnson DH, Wolff SN, Hainsworth JD, Porter LL, Grosh WW, Hande KR, Greco FA. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 3: 170-5. PMID 2981981 DOI: 10.1200/JCO.1985.3.2.170 |
0.324 |
|
| 1985 |
Hainsworth JD, Williams SD, Einhorn LH, Birch R, Greco FA. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 3: 666-71. PMID 2582097 DOI: 10.1200/JCO.1985.3.5.666 |
0.365 |
|
| 1983 |
Hainsworth JD, Workman R, Greco FA. Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer Cancer. 51: 161-165. PMID 6295592 |
0.332 |
|
| Show low-probability matches. |